Payer Perspectives
Subscribe
Sign in
Home
Notes
Archive
About
HealthIntel Weekly: GLP-1 Claims Surge 71% in Medicare Part D Between 2021 and 2023
Welcome to HealthIntel Weekly.
Mar 27
•
PayerPerspectives
1
Report: Global Medicine Use Will Continue to Grow, but U.S. Policies Will Have Impact
The use of medicines continues to increase around the world, driven mainly by immunology and oncology drugs, but a new report from the IQVIA Institute…
Mar 20
•
PayerPerspectives
3
1
Blues CEO Tops Public Insurance Giants on Pay in 2024
Health Care Service Corp. CEO led all major health insurer CEOs with $34.4 million in 2024 compensation.
Mar 19
•
PayerPerspectives
1
1
Most Popular
View all
Are Specialty Pharmacy Accelerators Next Wave of Payers’ Vertical Integration?
Sep 11, 2025
•
PayerPerspectives
1
Preparations for IRA’s Destruction of Part B Margins Could Begin in 2026
Jan 9
•
PayerPerspectives
6
2
Providers Prevail in Surprise Billing Disputes; HaloMD Emerges as Leading Middleman
Feb 20
•
PayerPerspectives
4
1
Payers Should Keep Eye on Evolving HAE Space
Feb 6
•
PayerPerspectives
5
1
HealthIntel Weekly: Centene Posts High MA Prior Authorization Volume and Denial Rate in 2024
Jan 30
•
PayerPerspectives
5
Five Fundamentals Behind LEON Health’s 5-Star Hat Trick
Oct 31, 2025
•
PayerPerspectives
2
1
Latest
Top
Discussions
HealthIntel Weekly: Humana and Centene Lead PDP Gains as Medicare Part D Enrollment Climbs in 2026
Welcome to HealthIntel Weekly.
Mar 13
•
PayerPerspectives
2
HealthIntel Weekly: Medicare Advantage Benefits Drops Sharply in 2026
Welcome to HealthIntel Weekly.
Feb 27
•
PayerPerspectives
2
Providers Prevail in Surprise Billing Disputes; HaloMD Emerges as Leading Middleman
HaloMD has emerged as the dominant middleman in surprise-billing arbitration, as disputes surge and legal scrutiny over the IDR system intensifies.
Feb 20
•
PayerPerspectives
4
1
Ambiguity Exists Around Drug Not Selected for Medicare Price Negotiations
One group of researchers managed to accurately predict almost all of the 15 drugs that CMS selected for the third round of Medicare price negotiations…
Feb 18
•
PayerPerspectives
2
1
HealthIntel Weekly: Medicare WISeR Model’s First-Year Impact Likely Modest
Welcome to HealthIntel Weekly.
Feb 13
•
PayerPerspectives
1
Payers Should Keep Eye on Evolving HAE Space
Although hereditary angioedema is a relatively rare disease, pharma manufacturers continue to pursue therapies for HAE. The FDA approved a handful of…
Feb 6
•
PayerPerspectives
5
1
HealthIntel Weekly: Centene Posts High MA Prior Authorization Volume and Denial Rate in 2024
Welcome to HealthIntel Weekly.
Jan 30
•
PayerPerspectives
5
See all
Payer Perspectives
We cover the managed care industry with unique angles on big stories, original interviews, and analysis you won’t find anywhere else.
Subscribe
Payer Perspectives
Subscribe
About
Archive
Sitemap
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
